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Osteoarthritis (OA) is the most common form of arthritis, is the leading cause of impaired mobility in the elderly,
and accounts for more than a third of chronic moderate to severe pain. As a degenerative joint disorder, OA affects
the whole joint and results in synovial hyperplasia, degradation of articular cartilage, subchondral sclerosis,
osteophyte formation, and chronic pain. Currently, there is no effective drug to decelerate OA progression and
molecular targets for drug development have been insufﬁciently investigated. Anti-OA drug development can
beneﬁt from more and precise knowledge of molecular targets for drug development. Runt-related transcription
factor 2 (Runx2) is a key transcription factor controlling osteoblast and chondrocyte differentiation and is among
the most promising potential therapeutic targets. Notably, Runx2 expression is upregulated in several murine OA
models, suggesting a role in disease pathogenesis. In this review article, we summarized recent ﬁndings on Runx2
related to OA development and evaluated its potential as a therapeutic target.
The translational potential of this article: A better understanding of the role of Runx2 in osteoarthritis pathogenesis
will contribute to the development of novel intervention of osteoarthritis disease.

Osteoarthritis (OA) is the most widespread joint disease worldwide,
and its prevalence has reached epidemic proportions [1]. By the year
2040, OA prevalence is projected to increase 49% to affect 78.4 million
US adults [2,3] and will be the dominant cause of physical disability and
morbidity among adults over 40 years of age [4]. OA is considered to be a
whole joint disease that involves cellular and molecular abnormalities,
such as articular cartilage degradation, hyperplasia of synovium, and
osteophyte formation [5].
Although there are no current disease-modifying therapies or interventions to slow disease progression, signiﬁcant progress has been
made on OA research in recent years. Studies using murine models of OA
indicate several growth factors, including transforming growth factor-β
(TGF-β), Wnt3a, and Indian hedgehog (Ihh), are involved in OA development [6–12]. Other signaling factors, such as Smad3, β-catenin, and
hypoxia-inducible factors -2α (HIF-2α), may also have a key role in OA
disease progression [6–11]. Interestingly, one common hallmark of OA
animal models and human OA cartilage samples is the upregulation of
runt-related transcription factor 2 (Runx2). Therefore, it has been hypothesized that Runx2 is a major transcriptional mediator that directly
regulates the expression of matrix degradation enzymes in articular

chondrocytes [12]. Since OA results from homeostatic failure of extracellular matrix degradation, Runx2 may serve as a key marker and
regulator of OA development and progression.
Here, we have aimed to summarize the role of Runx2 in normal and
diseased joint tissue, its regulation, and its regulatory targets. These
ﬁndings point to a molecular pathway linking Runx2 expression to OA
pathogenesis, which may be targeted for therapeutic intervention. The
aim of this review article is to (1) provide a comprehensive overview of
recent ﬁndings of Runx2 as a novel target for OA treatment, (2) describe
Runx2 as a central mediator of OA development in joint tissue, and (3)
understand OA molecular pathways to accelerate the development of
novel therapeutic strategies.
Runx2 upregulation in murine models of OA
Recent studies utilizing different murine OA models have illuminated
the critical role of Runx2 in the development of OA. The chondroprotective effects of Runx2 deletion from these studies, summarized
below, suggest that Runx2 may be an attractive molecular target for
future OA treatment research.
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Destabilization of the medial meniscus (DMM) murine model

β-catenin activation mice

Destabilization of the medial meniscus (DMM) surgery induces
changes in joint stability, similar to those seen in sport injury-induced
and aging-related OA [14]. Therefore, the DMM mouse model is
widely used to investigate OA mechanisms and treatment [14–17]. Using
this model, Liao et al. deleted Runx2 in chondrocytes in adult mice at 8
weeks of age and assessed the effect on OA progression [17]. Histological
analysis on Runx2 conditional knockout (cKO) mice following DMM
surgery showed a signiﬁcant decrease in the OA-like phenotype [17],
suggesting that Runx2 contributes to OA pathology. Consistent with this
model, cartilage ﬁssures, ﬁbrillation, and degradation at 12 weeks
postsurgery were reduced compared to the Cre-negative control [17].
Expression of matrix metalloproteinase-13 (MMP13), a potent enzyme
that targets the cartilage for degradation and is upregulated in late-stage
OA, was reduced at 8 to 12 weeks after DMM surgery in Runx2 cKO mice
[17]. Chondrocyte marker genes, such as Mmp9,13 and a disintegrin and
metalloproteinase with thrombospondin motifs (Adamts) 4,5,7,12, were
also markedly decreased [17]. Together, these ﬁndings indicate that the
deletion of Runx2 has substantial protective effects in murine chondrocytes following DMM surgery through the inhibition of multiple
matrix degradation enzymes.

Human genetic association studies have correlated abnormal
β-catenin signaling with OA development [28]. However, β-catenin
deletion or activation causes embryonic or immediate postnatal
lethality [29]; thus, our understanding of abnormal regulation of
β-catenin remains incomplete in animal models. Conditional gene
activation of β-catenin in cartilage has offered some insight into the role
of this protein in early cartilage development. In β-catenin activation
mice, Zhu et al. observed markedly diminished cartilage formation,
severe cartilage damage, and accelerated articular chondrocyte maturation [8]. Consistent with the OA development, β-catenin expression
was elevated in knee joint samples from OA patients [8]. Altogether,
the data are consistent with a key role for β-catenin in chondrocyte
differentiation and OA development.
Runx2 appears to have an important role downstream of β-catenin in
chondrocytes and endochondral bone development. Studies have established that β-catenin binds to the Runx2 promoter and activates Runx2
expression [30–33]. Analysis of gene expression and morphological
changes in vivo further demonstrated that Runx2 is upregulated in the
bone collar, perichondrium, and primary spongiosa when β-catenin
signaling is active[35–37]. Alterations in β-catenin mediated Runx2
activation also led to dysregulation of osteoblast and chondrocyte function, degenerative joints, and bone mass alterations [32]. Furthermore,
Runx2 upregulation through β-catenin is essential for the full differentiation of osteoblasts and for repression of the chondrogenic potential of
osteochondral progenitors [31,32]. These studies support the conclusion
that β-catenin mediated Runx2 action is essential in multiple steps of
chondrocyte differentiation and endochondral bone development.

TGF-β receptor II (Tgfbr2) conditional KO mice
The TGF-β/Smad signaling pathway contributes to OA development
and progression by mediating articular chondrocyte hypertrophy [7,
18–20]. TGF-β binds to TGF-β receptor II (Tgfbr2), leading to phosphorylation of heteromeric Smad2,3,4 complexes. The Smad complex
then translocates into the nucleus to interact with other DNA binding
proteins to regulate TGF-β/Smad signaling and induces OA pathology in
chondrocytes, as loss of TGF-β2 or TGF-β2 isoform leads to bone defects
in mice [21]. Overexpression of the dominant-negative Tgfbr2 (dnTgfbr2)
in transgenic mice causes extensive joint alterations that are similar to
human OA, including skeletal degeneration, proteoglycan reduction, and
progressive cartilage tissue degradation [18,22]. Smad3 KO mice and
Tgfbr2 cKO mice display the hallmarks of severe OA: progressive degradation of articular cartilage and osteophyte formation [6,7]. In chondrocytes of Tgfbr2 cKO mice, Runx2 mRNA and Runx2 protein levels were
found to be increased approximately 3- and 8-fold, respectively [13,26],
indicating that the pathology observed in Tgfbr2 cKO mice may be
mediated through Runx2.
Additional studies have also illustrated a relationship between TGFβ and Runx2 expression. Using Tgfbr2 cKO mice [7,23], Shen et al.
demonstrated that (1) Tgfbr2 inhibition in articular cartilage tissue
upregulated the principal regulators of the matrix components Mmp13
and Adamts5, (2) Deletion of Mmp13 and Adamts5 ameliorated the OA
disease progression prompted by the reduction of TGF-β/Smad
signaling in Tgfbr2 cKO mice [7,23], and (3) Runx2 binding site mutations largely prevented the inhibitory effect of TGF-β. Runx2 also
inﬂuenced the expression of Mmp13 and Adamts5 in vitro in cell culture
studies [7,23]. In addition, TGF-β treatment increased the expression of
cell cycle proteins while reducing Runx2 protein levels [24,25]. Among
the cell cycle proteins, cyclin D1/cyclin dependent kinase 4 (CDK4) was
speciﬁcally found to mediate the phosphorylation of Runx2, which
contributes to its eventual degradation by the proteasome [25,26].
Together, these ﬁndings suggest that impaired TGF-β signaling increases Mmp13 expression through a pathway that involves Runx2.
Since Runx2 induces hypertrophic chondrocyte marker genes and
Mmp13 is the downstream target of Runx2, these ﬁndings suggest that
Runx2 plays a critical role in mediating Mmp13 and Adamts5 expression
during OA development.
In addition to the targeting of articular cartilage, TGF-β also acts on
subchondral bone tissue and affects subchondral bone remodeling leading to alterations in OA progression [27].

Ihh transgenic mice
Hedgehog (Hh) signaling is a major modulator of skeletal development and chondrocyte differentiation during embryonic development
and infancy [30,33–38]. The major Hh ligand in chondrocytes is the
Indian hedgehog (Ihh), a protein that is produced and secreted by prehypertrophic chondrocytes. Mainly produced in cartilage, Ihh mediates
chondrocyte hypertrophy and endochondral bone formation by regulating the conserved targets [39]. Of particular interest to the Ihh
pathway is the activation of glioma-associated oncogene homolog (Gli).
Gli is a major activator of Runx2 expression that promotes osteoblast
formation, and leads to chondrocyte hypertrophy [40].
In healthy adult cartilage, Ihh expression normally decreases with
age to undetectable levels [41]. However, Ihh also mediates chondrocyte differentiation and hypertrophy in early OA and is associated
with cartilage degeneration. Analysis of human OA cartilage and synovial ﬂuid samples revealed that Ihh production was increased
2.6-fold in OA cartilage and by 37% in OA synovial ﬂuid [42]. The
dnTgfbr2 transgenic mice exhibited OA-like symptoms and increased
catabolic marker gene expression, including elevated Ihh expression
[18]. Ihh was also increased in response to early cartilage damage [41]
and was associated with increased Runx2, Mmp13, and collagen type II
alpha1 chain (Col2a1) expression. However, the complex network of
Ihh has been difﬁcult to study in murine models, as conventional Ihh
knockout mice are embryonic lethal [9,39,40].
To explore the speciﬁc role of Ihh in OA, Zhou et al. utilized cartilagespeciﬁc, inducible loss-of-function (LOF) Ihh transgenic mice. The mice
underwent DMM surgery at 3 months of age to induce posttraumatic OA.
Histological analysis of mice after DMM surgery demonstrated that Ihh
inactivation alleviates OA cartilage damage [43]. There was also a signiﬁcant decrease in downstream targets of Ihh, including genes Runx2,
Gli1, Gli2, Col10a1, and Mmp13 in cartilage tissues of Ihh transgenic mice
[43]. These ﬁndings demonstrate that the deletion of Ihh downregulates
Runx2 expression and suggests chondroprotection in patients in the early
stage of OA [43].
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Lin et al. conﬁrmed these ﬁndings and established the role of Ihh in
the regulation of Runx2 expression. In this study, articular chondrocytes
were ﬁrst transfected with Runx2 small interfering RNA (siRNA) and
were then treated with Hh-ligand or Hh-blocking agent. Hh positively
regulated Adamts5 in the control cells but did not regulate Adamts5 in
chondrocytes with Runx2 deletion [9]. Interestingly, this relationship
between Hh and Runx2 seems to be speciﬁc to OA [9]; Runx2 and Hh had
similar functions yet discrete roles during normal chondrocyte growth
and development [44,45]. Therefore, Hh was concluded to indirectly
regulate Adamts5 in OA through Hh-mediated expression of Runx2 [9].

In addition, bioinformatics predictions identiﬁed that Runx2 and C/
EBP-β are potent transcriptional partners in chondrocytes. Mice with dual
KO of Cebpb and Runx2 were resistant to OA, exhibiting decreased
cartilage degradation and decreased expression of Mmp13 [59]. Cebpb
and Runx2 were also coexpressed and colocalized in highly differentiated
chondrocytes during OA development in humans and in mice [59].
Hence, HIF-2α is a functional inducer, and Mmp13 is a target of Runx2
and C/EBP-β. Recent studies also demonstrated that excessive mechanical loading promotes OA development through activation of the
gremlin-1-NF-κB pathway [60].
In summary, (1) overexpression of Runx2 in mice increased the
number of cartilage proteases expressed in chondrocytes [12,17], (2)
Runx2 expression level was elevated in human cartilage obtained from
OA patients [12,17], (3) Upregulation of Runx2 activated MMP13 and
Adamts5, which are matrix degradation enzymes, (4) Runx2 regulates
Mmp13 gene by directly mediating Mmp13 gene transcription [61] or
through mitogen-activated protein kinase (MAPK) pathways [12,17],
and (5) After induction of knee joint instability, heterozygous global
Runx2 KO mice or chondrocyte-speciﬁc Runx2 deletion had decreased
cartilage destruction and osteophyte formation [11–13].

Nuclear factor-κB (NF-κB) KO mice
Nuclear factor-κB (NF-κB) orchestrates a wide range of stress-related
inﬂammatory responses and controls the growth, survival, and development of many cell types [46]. The pathology of OA chondrocytes in
aging and inﬂammatory models is exacerbated by prolonged NF-κB
activation [47,48]. Once activated, NF-κB homodimers translocate to the
nucleus and regulate genes involved in extracellular matrix remodeling
and chondrocyte terminal differentiation [49].
Many in vivo and in vitro studies demonstrate a role for NF-κB
signaling in promoting the production of procatabolic mediators,
increased production of proinﬂammatory cytokines, and the modiﬁcation of inﬂammatory transcription factors [10,11,47,50–52]. Two pivotal
kinases, I-κB kinase (IKK)-α and -β, activate NF-κB homodimers, but
studies have shown that these two kinases have differential effects on
chondrocyte differentiation [53,54]. Stable knockdown (KD) of IKK-α or
IKK-β compromised extracellular matrix (ECM) remodeling by different
pathways and to different degrees [53,54]. Of note, IKK-α KD chondrocytes resulted in pronounced hypertrophic differentiation of articular
chondrocytes [55]. Interestingly, the effects of IKK-mediated NF-κB
signaling were intrinsic to OA chondrocytes since only ECM remodeling
was affected, and OA-like differentiation is conserved only to chondrocytes [55].
Using IKK-β cKO mice as an OA model, Chang et al. also investigated
the role of IKK-NF-κB activation and its relation to Runx2 in OA developed: speciﬁcally, they studied the role of NF-κB in inﬂammationmediated inhibition of tissue regeneration [56]. Deletion of IKK-β
repressed expression of a well-established target of NF-κB, IL-6, in cells
treated with proinﬂammatory cytokines, TNF, and IL-17 [56]. This suggests that IKK-NF-κB may modulate hypertrophic-like conversion via the
control of Runx2, and thus, may be a pathway of interest to regulate
chondrocyte homeostasis in OA.

Runx2 functions in different joint tissues
Cartilage degradation is the hallmark of OA progression and indicates
the irreversibility of the disease. However, OA affects the whole joint,
and pathological changes seen in OA patients include thickening of
subchondral bone, osteophyte formation, synovial inﬂammation [63,64],
degeneration of ligaments, and hypertrophy of the joint capsule [65,66].
Changes in periarticular muscles, nerves, fat pads, and bursa can also
contribute to OA development [65]. All these pathological changes could
impact the joint and OA as a whole joint failure [65].
Articular chondrocytes
Articular chondrocytes are suspected to be major players in the
initiation and progression of OA. Chondrocytes are mainly affected by
inﬂammatory cytokines and cartilage-degrading enzymes, which work
together to create the characteristic phagocyte inﬁltration in joint tissue
associated with inﬂammation and OA [48].
Previous studies have shown that Runx2 was signiﬁcantly upregulated during hypertrophic differentiation and was associated with catabolic phenotypes observed in OA. Runx2 expression was tightly
correlated with increased expression of hypertrophic indicators, such as
Col10a1, Ihh, Mmp13, and Alp [67,68]. In articular chondrocytes, upregulation of Runx2 is induced by a variety of factors, including (1) the
β-catenin/lymphoid enhancer-binding factor (LEF)/T-cell factor (TCF)
complex through Wnt signal pathway [69], (2) canonical Wnt signaling,
which mediates the switch from Sox9 to Runx2 pathway [29,70], (3)
initiation of rapidly accelerated ﬁbrosarcoma (Raf)-mitogen-activated
protein (MEK1)/2-extracellular receptor kinase (ERK1)/2 cascade
through ﬁbroblast growth factors (FGF2) [71,72], and (4) HIF-2α
communication with both the β-catenin and NF-κB pathways [30].
In addition, it has been reported that during the progression of OA,
type X collagen, alkaline phosphatase, Runx2, and MMP13 are expressed
in articular chondrocytes with decreased proteoglycans and expanded
calciﬁed cartilage zones in articular cartilage [73,74].
In contrast, it has also been shown that the knocking down of Runx2
could not inhibit Col10a1 and Adamts5 expression and increased Mmp13
expression in human OA mesenchymal stem cells (MSCs). These ﬁndings
are opposite to the effects of Runx2 in chondrocytes [75].
In addition, DNA methylation studies by Bui et al. showed signiﬁcant
differential expression of Runx2 and changes in methylation patterns in
primary articular cartilages derived from patients with OA compared to
patients with no history of OA [76]. Consistent with this data, genetic
analysis by Roach et al. and Fernandez-Tajes et al. showed changes in
Runx2 methylation in human OA articular chondrocytes [77]. These

Hif-2α KO mice
One of the downstream effectors of NF-κB signaling is HIF-2α [47].
Studies have shown that HIF-2α regulates genes involved in endochondral ossiﬁcation by connecting inﬂammation-related chondrocyte hypertrophy and ECM degradation [10]. In HIF-2α heterozygous KO mice,
surgically induced OA development and progression was markedly suppressed [57], and HIF-2α haploinsufﬁciency decreased catabolic factors,
such as Mmp13, Mmp9 and Vegfa (vascular endothelial growth factor A)
[10,57]. HIF-2α also upregulated the production of the proinﬂammatory
cytokines IL-1β and TNF-α, which have been reported to be reduced
during the treatment with an IKK inhibitor [36,58]. These data indicate
that the NF-κB-targeted transcription factor HIF-2α increases the production of catabolic factors and proinﬂammatory cytokines.
Further studies suggest that the combined action of C/EBP-β (CCAATenhancer-binding protein beta) and Runx2 is essential to HIF-2α to
trigger Mmp13 expression [59]. Site-directed mutagenesis within the
Mmp13 promoter signiﬁcantly represses HIF-2α promoter activity
induced by C/EBP-β and Runx2 [59]. Similarly, retroviral overexpression
of HIF-2α enhanced Cebpb expression in primary chondrocytes, while
dominant-negative HIF-2α suppressed Cebpb expression in chondrocytes
[59].
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patients prior to knee replacement. Surprisingly, an explant culture of the
avascular part of the inner meniscus obtained from an OA patient led to
the discovery of a group of migratory, multilineage, and multipotent cells
[92]. These new cells, which have been termed as human meniscus
progenitor cells (MPCs), were found only in the diseased tissue but not in
healthy controls. These MPCs seem to be modulated by Runx2, consistent
with previous studies. There was a greater level of Runx2 and a simultaneous reduction of TGF-β in diseased meniscal specimens. There were
almost undetectable levels of Runx2 and a reduction in Runx2 mRNA in
healthier specimens. When 3D explant cultures of MPCs from human
inner meniscal tissue were differentiated into cells of chondrogenic
lineage, cells from damaged meniscus showed no Runx2 levels and
increased Sox9 levels. Knocking down of Runx2 via siRNA in MPCs
demonstrated the upregulation of Sox9 and Smad2. The data correlate
with previous ﬁndings that the regulation of Runx2 is the key to OA
development. These ﬁndings also suggest that Runx2 is a major regulatory factor of OA progression in the meniscus and is a potential drug
target for regeneration in the diseased meniscus.
These data were also recapitulated in the aforementioned studies
using the DMM model in Runx2 KO mice [17,100]. Surgical destabilization of the medial meniscus is a technique widely used as an OA model,
as DMM surgery leads to degeneration of articular cartilage and shows
OA-like pathology in the knee joint [17]. With the inhibition of Runx2 in
the DMM-induced OA mouse model, Liao et al. have demonstrated that
Runx2 is a signiﬁcant contributor to OA disease in the meniscus and can
serve as a target for potential therapeutics.

studies indicate a role for Runx2 as a master transcription factor in
articular chondrocyte differentiation in OA.
Synovial cells
Studies by Scanzello et al. have characterized synovial pathology in
the development or progression of OA, especially in the context of
inﬂammation and pain [63]. Synovia with increased inﬂammation were
associated with unique chemokines and cytokines that may represent a
signature for OA development [75,78]. Speciﬁcally, cytokines known to
have catabolic effects on chondrocytes, including IL-8, CCL-5, IL-1, IL-6,
and TNF-α, were increased in the synovia [75,79–81]. Even in the
absence of phagocyte inﬁltration and inﬂammation of joint tissue
inﬂammation, OA synovial ﬂuid had elevated levels of inﬂammatory
cytokines [75]. Synovial inﬂammation, whether dependent or independent of joint inﬂammation, is a critical factor in OA pathogenesis and
warrants further investigation.
Interestingly, ﬁbroblast growth factor 2 (FGF-2) was found to be
present in synovial ﬂuid and highly correlated with the severity of
cartilage degeneration in OA [72]. FGF2 has been implicated in cartilage
homeostasis by controlling chondrocyte differentiation [82,83]. In
human OA cartilage, FGF-2 activated Runx2 through MEK/ERK signaling
and upregulated the expression of Mmp13. Correspondingly, inhibition of
the MEK/ERK pathway impeded Runx2 activation by FGF-2, and treatment with FGF-2 increased Runx2 phosphorylation [84,85]. Together,
FGF-2, which accrues in synovial ﬂuids of OA joints [72], is suggested to
contribute to Runx2 activation leading to Mmp13 upregulation.

Up-regulation of Runx2 in joint tissue
Subchondral bone cells
Since OA is a whole joint disease, its initiation and progression
remain poorly understood, especially at the molecular level. Recent evidence suggests epigenetic and microRNA (miRNA) alterations may play
a role in OA disease pathology. Several miRNAs and DNA methylation
patterns have been reported to regulate Runx2 expression in OA cartilage. These ﬁndings suggest that epigenetic modiﬁcations or miRNA
regulation may serve as important mediators of OA.

It has been well established that Runx2 is critical for skeletal, cartilage, and condylar development [86–88]. Shibata et al. have demonstrated that the absence of condylar cartilage development in Runx2 /
mice and Runx2 global KO mice display stunted growth and die shortly
after birth due to an absolute absence of bone tissue [86–88]. This suggests that Runx2 is essential for condylar cartilage formation [87].
Since Runx2 plays a central role in chondrocyte hypertrophy, the
characteristic of OA pathogenesis, Liao et al. studied its speciﬁc role in
subchondral bone cells using Runx2 cKO mice. Interestingly, Runx2
deletion blocks chondrocyte translocation into the subchondral bone
region and inhibits chondrocyte transdifferentiation into progenitor cells
[89]. Comparatively, histological analysis demonstrated extensive
chondrocyte growth in condylar cartilage and subchondral bone in
control mice, indicating a key role for Runx2 in subchondral bone
remodeling [89]. Runx2 was also highly expressed in proliferative and
hypertrophic chondrocytes, suggesting Runx2 regulates subchondral
bone remodeling. Combined with studies demonstrating that Runx2
deletion causes loss of hypertrophic chondrocytes [17], the ﬁndings by
Shibata et al. indicate that Runx2 is essential in orchestrating the proliferation and hypertrophic progression at the postnatal stage.

MicroRNA regulation of Runx2
MicroRNAs are short non-coding RNA molecules that regulate gene
expression, especially in the context of embryonic and hematopoietic
stem cells [101]. Although our understanding of miRNAs and their role in
mesenchymal stem cells (MSCs) is scant, several transcription factors are
known to modulate MSC differentiation into chondrocytes and osteoblasts. Of the transcriptional factors identiﬁed, Runx2 plays a unique
multifunctional role in chondrogenesis and osteogenesis [102–104]. The
deletion of the miRNA processing enzyme Dicer signiﬁcantly reduced the
expression of Runx2-related miRNAs and interrupted bone formation.
Speciﬁcally, miR-105 binds to Runx2 in chondrocytes [105], and the
downregulation of miR-105 in OA cartilage was associated with
decreased Runx2, Adamts7, and Adamts12 expression [105]. Additionally, miRNA-145 indirectly regulates Runx2 by relieving Sox9-mediated
repression of Runx2, and thus, the overexpression of miR-145-induced
mRNA levels of Runx2 [106]. Similarly, miR-140 targeted and promoted chondrocyte hypertrophy and was speciﬁcally expressed in
cartilage tissue [107]. Its chondroprotective effect against OA progression has been linked to the downregulation of several proteins involved
in cartilage destruction, such as Mmp13 and Admats5 [108,109]. Lastly,
miR-204 decreased chondrocyte proliferation and ameliorated the
OA-like phenotype in rodent models in a Runx2-dependent mechanism
[102,104]. Since Runx2 protein expression was signiﬁcantly increased by
miR-204 Antagomir, it suggests that miR-204 is an endogenous attenuator of Runx2 in MSCs [102,104,110]. Consistent with the in vitro ﬁndings, miR-204/miR-211 double KO mice developed severe,
time-dependent OA development and progression, indicating the key
role of regulation of Runx2 in OA development [111]. Together, it can be

Meniscus
Changes in the meniscus are well documented in OA, and knee joint
degeneration often starts with meniscal lesions [67,90–92]. In fact, this
high interdependency of OA and the meniscus is why meniscectomy is
now obsolete, as the procedure inevitably leads to the development of OA
[90–92]. While the outer, vascularized meniscus has been shown to return to normal function after surgical repair [93,94], it is traditionally
thought that degeneration of the inner meniscus is difﬁcult to address
because it is avascular, and thus, unable to self-regenerate to full functionality [95–97]. However, recent studies have revealed that the inner
meniscus responds to growth factors and ﬁbrin clots [92,94,98,99], and
thus, it has been proposed that the inner meniscus harbors cells capable
of regeneration [91]. Of note, Muhammad et al. described the regenerative potential of avascular meniscal tissue obtained from late-stage OA
135
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Runx2 siRNA [127]. Chromatin immunoprecipitation (ChIP) assay
demonstrated that Runx2 directly binds to the Mmp13 promoter in rat
chondrosarcoma cells [7], which was conﬁrmed by clustered regularly
interspaced short palindromic repeats (CRISPR) gene deletion studies. It
has been determined that Mmp13 expression was mediated by Runx2 via
a complex arrangement of enhancers [124,128,129]. Combined with the
observation that Mmp13 is a marker of chondrocyte hypertrophy [38],
Runx2 is a key mediator of stress-induced Mmp13 expression [125,127]
and play a key role in OA pathogenesis [62,84,126,130].

concluded that Runx2-miRNA interaction is an area of interest to OA
development and progression.
Epigenetic regulation of Runx2
Epigenetics alter the gene expression without changes in the DNA
sequence and may signiﬁcantly contribute to gene regulation and protein
expression. Although the genetic code is identical for every cell in the
body, epigenetic regulation and changes are often location- and cell-typespeciﬁc [112]. Therefore, disruption of an established epigenetic
network can cause several major pathologies, including OA [114,115].
Several genome-wide proﬁle studies revealed that the DNA
methylation-dependent alteration might contribute to biological processes in human OA articular chondrocytes [113–115]. Fernandez-Tajes
et al. identiﬁed 91 differentially methylated probes that were tightly
associated with a speciﬁc cluster of OA patients. Among these genes,
Runx2 methylation was markedly decreased [113]. Similarly, studies by
Bui et al. examined the effect of DNA methyltransferase inhibitor Aza on
the expression of genes associated with cartilage, epigenetics, and cell
senescence. Gene expression analysis revealed that Runx2 was differently
expressed between control and OA chondrocytes treated with Aza [76].
Most signiﬁcantly, genome-wide methylation analysis using cartilage
DNA revealed seven CpG sites located 82 kb upstream of Runx2 and
Supt3h, a chromatin remodeling protein [115]. Additionally, the UK
GWAS arcOGEN study [116] identiﬁed a common single nucleotide
polymorphism (SNP) associated with OA susceptibility, and Rice et al.
showed that this SNP was located within and ﬂanking differentially
methylated regions. OA disease progression was strongly affected by
genetic and epigenetic activity within this region. It was concluded that
Runx2 was strongly associated with OA susceptibility and was a principal
target in modulating the methylation patterns of OA disease [117].
Because Runx2 expression is modulated by DNA methylation and is
associated with OA genetic risk, Runx2 epigenetic regulation is a realm
for further investigation and potential intervention.

Adamts
Over the past decade, many ex vivo and in vivo studies have demonstrated that signiﬁcant upregulation of Runx2 may lead to catabolic responses in chondrocytes [19,20,131–134]. The observed changes in
TGF-β, β-catenin, Ihh, and FGF pathways have shown to converge on
Runx2 regulation, primarily throughout the expression of MMPs and
Adamts activity [59,120,134]. Thirunavukkarasu et al. demonstrated
that Runx2 overexpression could increase Adamts5 expression by 5- and
7-fold over the control in human chondrosarcoma cells and in primary
bovine chondrocytes, respectively [135]. In another study, cotransfection with Runx2 siRNA together with Tgfbr2 siRNA repressed stimulation
of Adamts5 and Mmp13 expression [7]. CTS studies also conﬁrmed that
Adamts5 expression is controlled by Runx2, as CTS induction of Runx2
expression was also associated with increased Adamts5 expression [127].
Similarly, the transfection of Runx2 siRNA resulted in signiﬁcant
downregulation of Adamts5 [127]. In addition, Adamts5 KO mice
noticeably reduced the severity of cartilage destruction with surgically
induced joint instability. This study demonstrated that Adamts5 single
gene deletion abrogated OA-like cartilage destruction and concluded that
Adamts5 is a primary factor responsible for OA cartilage degradation
[13]. With noteworthy data showcasing Runx2 as a key transcription
factor regulating these genes, targeting Runx2 may be a key therapeutic
strategy in OA cartilage to ameliorate disease onset and progression.

Runx2 downstream target genes

Conclusion

OA disease progression is highly complex and involves numerous
interrelated events that eventually lead to decreased chondrocyte protein
synthesis and catabolic protease activation. Speciﬁcally, matrix metalloproteinases (MMPs) and aggrecanases (Adamts) contribute widely to
aggrecan loss. A subfamily of collagenases, MMP1, 8, and 13, are
involved in the cartilage destruction. MMP1 is expressed in ﬁbroblast and
macrophages [118], MMP8 cleaves aggrecan at speciﬁc sites [119], and
MMP13 interacts primarily with type II collagen [119]. Adamts4
(aggrecanase 1) and Adamts5 (aggrecanase 2) have been associated with
fundamental structural degradation underlying human OA. Although
there is no universal agreement of which primary aggrecanase is
responsible for aggrecan degradation in human OA [120–122], Adamts
have signiﬁcant potential for novel OA drug design.

In summary, Runx2 was identiﬁed as a major marker of OA disease
that is highly expressed in OA murine models and human patients. Runx2
was upregulated in multiple OA mouse models, including DMM, Tgfbr2
conditional KO, β-catenin activation, Ihh transgenic, and NF-κB KO mice
models. In most studies, multiple matrix degradation enzymes, Mmp13
and Adamts5, and their corresponding regulatory genes were highly
involved, providing compelling evidence for Runx2 as a transcriptional
factor that controls the expression of these genes. Together, these studies
suggest that expression of Runx2 and development of OA is through a
ﬁne balance of multiple factors, especially through the activation of
β-catenin, Wnt, Ihh, IKK-α, TGF-β, and Hif-2α signaling pathways. Many
studies also implicated the role of Runx2 in different joint tissues, such as
the meniscus, synovial cells, and subchondral bone cells. Therefore,
Runx2 could serve as a novel molecular target for not only OA progression but also a target to reduce pain and inﬂammation associated with OA
disease. In addition to Runx2, Runx1 has also been shown to be involved
in OA development which may serve as a drug target for OA treatment
[136].

MMPs
In recent studies, MMP13 has been shown as a downstream target of
Runx2. In Runx2 KO mice, OA pathology and progression were ameliorated due to a mechanism that involved a signiﬁcant decrease in Mmp13
expression [123]. Runx2 directly regulates Mmp13 promotor activity and
MMP13 expression in vivo. Real-time RT-PCR analysis demonstrated
upregulated Runx2 mRNA expression was correlated with decreased
Mmp13 expression in vivo [124]. Hypertrophic chondrocyte markers,
such as Mmp13 and Col10a1, were upregulated in vitro under cyclic
tensile strain (CTS) [125]. This complex mechanoresponsive mechanism
was found to be under the control of the Runx2/Cbfa1 pathway that leads
to the regulation of Mmp13 expression in primary chondrocytes [13,84,
124–126]. Tetsunaga et al. also demonstrated the upregulation of Mmp13
with overexpression of Runx2 and the downregulation of Mmp13 with

Conﬂict of Interest
The authors have no conﬂicts of interest to disclose in relation to this
article.
Acknowledgments
This work was supported by National Institutes of Health Grants
R01AR069605 to R.J.O., and R01 AR075860 to J.S.
136

D. Chen et al.

Journal of Orthopaedic Translation 23 (2020) 132–139

References

[26] Shen R, Wang X, Drissi H, Liu F, O'Keefe RJ, Chen D. Cyclin D1-cdk4 induce runx2
ubiquitination and degradation. J Biol Chem 2006;281(24):16347–53. https://
doi.org/10.1074/jbc.M603439200.
[27] Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of TGF–β signaling
in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nat Med
2013;19(6):704–12. https://doi.org/10.1038/nm.3143.
[28] Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships
and patterns. Bioessays 2002;24(9):811–20. https://doi.org/10.1002/bies.10136.
[29] Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, et al.
Interactions between Sox9 and beta-catenin control chondrocyte differentiation.
Genes Dev 2004;18(9):1072–87. https://doi.org/10.1101/gad.1171104.
[30] Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in
mesenchymal progenitors controls osteoblast and chondrocyte differentiation
during vertebrate skeletogenesis. Dev Cell 2005;8(5):739–50. https://doi.org/
10.1016/j.devcel.2005.03.016.
[31] Wu Q, Chen D, Zuscik MJ, O'Keefe RJ, Rosier RN. Overexpression of Smurf2
stimulates endochondral ossiﬁcation through upregulation of β-catenin. J Bone
Miner Res 2008;23(4):552–63. https://doi.org/10.1359/JBMR.071115.
[32] Wu Q, Zhu M, Rosier RN, Zuscik MJ, O'Keefe RJ, Chen D. β-catenin, cartilage, and
osteoarthritis. Ann N Y Acad Sci 2010;1192(1):344–50. https://doi.org/10.1111/
j.1749-6632.2009.05212.x.
[33] Jayasuriya CT, Hu N, Li J, Lemme N, Terek R, Ehrlich MG, et al. Molecular
characterization of mesenchymal stem cells in human osteoarthritis cartilage
reveals contribution to the OA phenotype. Sci Rep 2018;8(1):7044. https://
doi.org/10.1038/s41598-018-25395-8.
[34] Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, et al. PTH/PTHrP
receptor in early development and Indian hedgehog-regulated bone growth.
Science 1996;273(5275):663–6.
[35] Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of
rate of cartilage differentiation by Indian hedgehog and PTH-related protein.
Science 1996;273(5275):613–22.
[36] Kobayashi T, Soegiarto DW, Yang Y, Lanske B, Schipani E, McMahon AP, et al.
Indian hedgehog stimulates periarticular chondrocyte differentiation to regulate
growth plate length independently of PTHrP. J Clin Invest 2005;115(7):1734–42.
https://doi.org/10.1172/JCI24397.
[37] Hilton MJ, Tu X, Long F. Tamoxifen-inducible gene deletion reveals a distinct cell
type associated with trabecular bone, and direct regulation of PTHrP expression
and chondrocyte morphology by Ihh in growth region cartilage. Dev Biol 2007;
308(1):93–105. https://doi.org/10.1016/j.ydbio.2007.05.011.
[38] Mak KK, Kronenberg HM, Chuang P-T, Mackem S, Yang Y. Indian hedgehog
signals independently of PTHrP to promote chondrocyte hypertrophy.
Development 2008;135(11):1947–56. https://doi.org/10.1242/dev.018044.
[39] Nakamura T, Aikawa T, Iwamoto-Enomoto M, Iwamoto M, Higuchi Y, Paciﬁci M,
et al. Induction of osteogenic differentiation by hedgehog proteins. Biochem
Biophys Res Commun 1997;237(2):465–9.
[40] Kim E-J, Cho S-W, Shin J-O, Lee M-J, Kim K-S, Jung H-S. Ihh and Runx2/Runx3
signaling interact to coordinate early chondrogenesis: a mouse model. PloS One
2013;8(2):e55296. https://doi.org/10.1371/journal.pone.0055296.
[41] Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very
early focal cartilage degeneration is associated with upregulation of chondrocyte
differentiation related genes in early human articular cartilage lesions. J
Rheumatol 2005;32(5):876–86.
[42] Wei F, Zhou J, Wei X, Zhang J, Fleming BC, Terek R, et al. Activation of indian
hedgehog promotes chondrocyte hypertrophy and upregulation of MMP-13 in
human osteoarthritic cartilage. Osteoarthritis Cartilage 2012;20(7):755–63.
https://doi.org/10.1016/j.joca.2012.03.010.
[43] Zhou J, Chen Q, Lanske B, Fleming BC, Terek R, Wei X, et al. Disrupting the Indian
hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis
progression in Col2a1-CreERT2; Ihhﬂ/ﬂ mice. Arthritis Res Ther 2014;16(1):R11.
https://doi.org/10.1186/ar4437.
[44] Adams SL, Cohen AJ, Lassova L. Integration of signaling pathways regulating
chondrocyte differentiation during endochondral bone formation. J Cell Physiol
2007;213(3):635–41. https://doi.org/10.1002/jcp.21262.
[45] Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, Inoue K, et al. Runx2 and
Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth
through induction of Indian hedgehog. Genes Dev 2004;18(8):952–63. https://
doi.org/10.1101/gad.1174704.
[46] Goldring MB, Otero M. Inﬂammation in osteoarthritis. Curr Opin Rheumatol
2011;23(5):471–8. https://doi.org/10.1097/BOR.0b013e328349c2b1.
[47] Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling:
multiple angles to target OA. Curr Drug Targets 2010;11(5):599–613.
[48] Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;
43(9):1916–26. https://doi.org/10.1002/1529-0131(200009)43:9<1916::AIDANR2>3.0.CO;2-I.
[49] Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB
signaling module. Oncogene 2006;25(51):6706–16. https://doi.org/10.1038/
sj.onc.1209933.
[50] Hashimoto K, Otero M, Imagawa K, de Andres MC, Coico JM, Roach HI, et al.
Regulated transcription of human matrix metalloproteinase 13 (MMP13) and
interleukin-1β (IL1B) genes in chondrocytes depends on methylation of speciﬁc
proximal promoter CpG sites. J Biol Chem 2013;288(14):10061–72. https://
doi.org/10.1074/jbc.M112.421156.
[51] Peng H, Tan L, Osaki M, Zhan Y, Ijiri K, Tsuchimochi K, et al. ESE-1 Is a potent
repressor of type II collagen gene (COL2A1) transcription in human chondrocytes.
J Cell Physiol 2008;215(2):562–73. https://doi.org/10.1002/jcp.21338.

[1] van Baar ME, Dekker J, Lemmens JA, Oostendorp RA, Bijlsma JW. Pain and
disability in patients with osteoarthritis of hip or knee: the relationship with
articular, kinesiological, and psychological characteristics. J Rheumatol 1998;
25(1):125–33.
[2] Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated
activity limitations. Arthritis Rheum 2006;54(1):226–9. https://doi.org/10.1002/
art.21562.
[3] Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected
prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable
Activity limitation among US adults, 2015–2040. Arthritis Rheum 2016;68(7):
1582–7. https://doi.org/10.1002/art.39692.
[4] Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al.
Estimates of the prevalence of arthritis and other rheumatic conditions in the
United States. Part I. Arthritis Rheum 2008;58(1):15–25. https://doi.org/
10.1002/art.23177.
[5] Dieppe PA, Lohmander LS. Pathogenesis and management of pain in
osteoarthritis. Lancet 2005;365(9463):965–73. https://doi.org/10.1016/S01406736(05)71086-2.
[6] Yang X, Chen L, Xu X, Li C, Huang C, Deng CX. TGF-beta/Smad3 signals repress
chondrocyte hypertrophic differentiation and are required for maintaining
articular cartilage. J Cell Biol 2001;153(1):35–46.
[7] Shen J, Li J, Wang B, Jin H, Wang M, Zhang Y, et al. Deletion of the transforming
growth factor β receptor type II gene in articular chondrocytes leads to a
progressive osteoarthritis-like phenotype in mice. Arthritis Rheum 2013;65(12):
3107–19. https://doi.org/10.1002/art.38122.
[8] Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin
signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult
β-catenin conditional activation mice. J Bone Miner Res 2009;24(1):12–21.
https://doi.org/10.1359/JBMR.080901.
[9] Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, et al. Modulating
hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med 2009;
15(12):1421–5. https://doi.org/10.1038/nm.2055.
[10] Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, et al. Transcriptional
regulation of endochondral ossiﬁcation by HIF-2α during skeletal growth and
osteoarthritis development. Nat Med 2010;16(6):678–86. https://doi.org/
10.1038/nm.2146.
[11] Yang S, Kim J, Ryu J-H, Oh H, Chun C-H, Kim BJ, et al. Hypoxia-inducible factor2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med
2010;16(6):687–93. https://doi.org/10.1038/nm.2153.
[12] Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, et al. Osteoarthritis: toward
a comprehensive understanding of pathological mechanism. Bone Res 2017;5:
16044. https://doi.org/10.1038/boneres.2016.44.
[13] Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial
meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse.
Osteoarthritis Cartilage 2007;15(9):1061–9. https://doi.org/10.1016/
j.joca.2007.03.006.
[14] Lampropoulou-Adamidou K, Lelovas P, Karadimas EV, Liakou C,
Triantaﬁllopoulos IK, Dontas I, et al. Useful animal models for the research of
osteoarthritis. Eur J Orthop Surg Traumatol 2014;24(3):263–71. https://doi.org/
10.1007/s00590-013-1205-2.
[15] Lorenz J, Gr€
assel S. Experimental osteoarthritis models in mice. Methods Mol Biol
2014;1194:401–19. https://doi.org/10.1007/978-1-4939-1215-5_23.
[16] Thysen S, Luyten FP, Lories RJU. Targets, models and challenges in osteoarthritis
research. Disease Model Mech 2015;8(1):17–30. https://doi.org/10.1242/
dmm.016881.
[17] Liao L, Zhang S, Gu J, Takarada T, Yoneda Y, Huang J, et al. Deletion of Runx2 in
articular chondrocytes decelerates the progression of DMM-induced osteoarthritis
in adult mice. Sci Rep 2017;7(1):2371. https://doi.org/10.1038/s41598-01702490-w.
[18] Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, et al.
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse
skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J
Cell Biol 1997;139(2):541–52.
[19] Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-beta and
osteoarthritis. Osteoarthritis Cartilage 2007;15(6):597–604. https://doi.org/
10.1016/j.joca.2007.02.005.
[20] Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den
Berg WB. Reduced transforming growth factor-beta signaling in cartilage of old
mice: role in impaired repair capacity. Arthritis Res Ther 2005;7(6):R1338–47.
https://doi.org/10.1186/ar1833.
[21] Dünker N, Krieglstein K. Targeted mutations of transforming growth factor-beta
genes reveal important roles in mouse development and adult homeostasis. Eur J
Biochem 2000;267(24):6982–8.
[22] Buckwalter JA, Brown TD. Joint injury, repair, and remodeling: roles in posttraumatic osteoarthritis. Clin Orthop Relat Res 2004;423:7–16.
[23] Shen J, Li S, Chen D. TGF-β signaling and the development of osteoarthritis. Bone
Res 2014;2:14002. https://doi.org/10.1038/boneres.2014.2.
[24] McCarthy TL, Centrella M. Novel links among Wnt and TGF-β signaling and
Runx2. Mol Endocrinol 2010;24(3):587–97. https://doi.org/10.1210/me.20090379.
[25] Jonason JH, Xiao G, Zhang M, Xing L, Chen D. Post-translational regulation of
Runx2 in bone and cartilage. J Dent Res 2009;88(8):693–703. https://doi.org/
10.1177/0022034509341629.

137

D. Chen et al.

Journal of Orthopaedic Translation 23 (2020) 132–139

[52] Otero M, Plumb DA, Tsuchimochi K, Dragomir CL, Hashimoto K, Peng H, et al.
E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13)
transcriptional control in articular chondrocytes under proinﬂammatory stress. J
Biol Chem 2012;287(5):3559–72. https://doi.org/10.1074/jbc.M111.265744.
[53] Olivotto E, Otero M, Marcu KB, Goldring MB. Pathophysiology of osteoarthritis:
canonical NF-κB/IKKβ-dependent and kinase-independent effects of IKKα in
cartilage degradation and chondrocyte differentiation. RMD Open 2015;1(Suppl
1). https://doi.org/10.1136/rmdopen-2015-000061.
[54] Olivotto E, Borzi RM, Vitellozzi R, Pagani S, Facchini A, Battistelli M, et al.
Differential requirements for IKKalpha and IKKbeta in the differentiation of
primary human osteoarthritic chondrocytes. Arthritis Rheum 2008;58(1):227–39.
https://doi.org/10.1002/art.23211.
[55] Olivotto E, Otero M, Astolﬁ A, Platano D, Facchini A, Pagani S, et al. IKKα/CHUK
regulates extracellular matrix remodeling independent of its kinase activity to
facilitate articular chondrocyte differentiation. PloS One 2013;8(9):e73024.
https://doi.org/10.1371/journal.pone.0073024.
[56] Chang J, Liu F, Lee M, Wu B, Ting K, Zara JN, et al. NF-κB inhibits osteogenic
differentiation of mesenchymal stem cells by promoting β-catenin degradation.
Proc Natl Acad Sci USA 2013;110(23):9469–74. https://doi.org/10.1073/
pnas.1300532110.
[57] Saito T, Tanaka S. Molecular mechanisms underlying osteoarthritis development:
notch and NF-κB. Arthritis Res Ther 2017;19(1):94. https://doi.org/10.1186/
s13075-017-1296-y.
[58] Kobayashi H, Chang SH, Mori D, Itoh S, Hirata M, Hosaka Y, et al. Biphasic
regulation of chondrocytes by rela through induction of anti-apoptotic and
catabolic target genes. Nat Commun 2016;7:13336. https://doi.org/10.1038/
ncomms13336.
[59] Hirata M, Kugimiya F, Fukai A, Saito T, Yano F, Ikeda T, et al. C/EBPβ and RUNX2
cooperate to degrade cartilage with MMP-13 as the target and HIF-2α as the
inducer in chondrocytes. Hum Mol Genet 2012;21(5):1111–23. https://doi.org/
10.1093/hmg/ddr540.
[60] Chang SH, Mori D, Nakamoto H, Okada K, Taniguchi Y, Sugita S, et al. Excessive
mechanical loading promotes osteoarthritis through the gremlin-1-NF-κB
pathway. Nat Commun 2019 (Accepted).
[61] Wang M, Tang D, Shu B, Wang B, Jin H, Hao S, et al. Conditional activation of
β-catenin signaling in mice leads to severe defects in intervertebral disc tissue.
Arthritis Rheum 2012;64(8):2611–23. https://doi.org/10.1002/art.34469.
[62] Chen CG, Thuillier D, Chin EN, Alliston T. Chondrocyte-intrinsic Smad3 represses
Runx2-inducible matrix metalloproteinase 13 expression to maintain articular
cartilage and prevent osteoarthritis. Arthritis Rheum 2012;64(10):3278–89.
https://doi.org/10.1002/art.34566.
[63] Scanzello CR, McKeon B, Swaim BH, DiCarlo E, Asomugha EU, Kanda V, et al.
Synovial inﬂammation in patients undergoing arthroscopic meniscectomy:
molecular characterization and relationship to symptoms. Arthritis Rheum 2011;
63(2):391–400. https://doi.org/10.1002/art.30137.
[64] Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High
abundance synovial ﬂuid proteome: distinct proﬁles in health and osteoarthritis.
Arthritis Res Ther 2007;9(2):R36. https://doi.org/10.1186/ar2172.
[65] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the
joint as an organ. Arthritis Rheum 2012;64(6):1697–707. https://doi.org/
10.1002/art.34453.
[66] Goldring MB, Otero M, Plumb DA, Dragomir C, Favero M, El Hachem K, et al.
Roles of inﬂammatory and anabolic cytokines in cartilage metabolism: signaling
and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur
Cell Mater 2011;21:202–20.
[67] Kamekura S, Kawasaki Y, Hoshi K, Shimoaka T, Chikuda H, Maruyama Z, et al.
Contribution of runt-related transcription factor 2 to the pathogenesis of
osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum
2006;54(8):2462–70. https://doi.org/10.1002/art.22041.
[68] Higashikawa A, Saito T, Ikeda T, Kamekura S, Kawamura N, Kan A, et al.
Identiﬁcation of the core element responsive to runt-related transcription factor 2
in the promoter of human type X collagen gene. Arthritis Rheum 2009;60(1):
166–78. https://doi.org/10.1002/art.24243.
[69] Dong Y-F, Soung DY, Schwarz EM, O’Keefe RJ, Drissi H. Wnt induction of
chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol
2006;208(1):77–86. https://doi.org/10.1002/jcp.20656.
[70] Hill TP, Sp€
ater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/betacatenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev
Cell 2005;8(5):727–38. https://doi.org/10.1016/j.devcel.2005.02.013.
[71] Yan D, Chen D, Im H-J. Fibroblast growth factor-2 promotes catabolism via
FGFR1-Ras-Raf-MEK1/2-ERK1/2 axis that coordinates with the PKCδ pathway in
human articular chondrocytes. J Cell Biochem 2012;113(9):2856–65. https://
doi.org/10.1002/jcb.24160.
[72] Orito K, Koshino T, Saito T. Fibroblast growth factor 2 in synovial ﬂuid from an
osteoarthritic knee with cartilage regeneration. J Orthop Sci 2003;8(3):294–300.
https://doi.org/10.1007/s10776-003-0647-6.
[73] van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms.
Osteoarthritis Cartilage 2011;19(4):338–41. https://doi.org/10.1016/
j.joca.2011.01.022.
[74] Tchetina EV. Developmental mechanisms in articular cartilage degradation in
osteoarthritis. Arthritis 2011;2011:683970. https://doi.org/10.1155/2011/
683970.
[75] Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis.
Bone 2012;51(2):249–57. https://doi.org/10.1016/j.bone.2012.02.012.
[76] Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, et al. cAMP response
element-binding (CREB) recruitment following a speciﬁc CpG demethylation leads

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

138

to the elevated expression of the matrix metalloproteinase 13 in human articular
chondrocytes and osteoarthritis. Faseb J 2012;26(7):3000–11. https://doi.org/
10.1096/fj.12-206367.
Roach HI, Yamada N, Cheung KSC, Tilley S, Clarke NMP, Oreffo ROC, et al.
Association between the abnormal expression of matrix-degrading enzymes by
human osteoarthritic chondrocytes and demethylation of speciﬁc CpG sites in the
promoter regions. Arthritis Rheum 2005;52(10):3110–24. https://doi.org/
10.1002/art.21300.
Ling SM, Patel DD, Garnero P, Zhan M, Vaduganathan M, Muller D, et al. Serum
protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage
2009;17(1):43–8. https://doi.org/10.1016/j.joca.2008.05.004.
Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, et al. Local
cytokine proﬁles in knee osteoarthritis: elevated synovial ﬂuid interleukin-15
differentiates early from end-stage disease. Osteoarthritis Cartilage 2009;17(8):
1040–8. https://doi.org/10.1016/j.joca.2009.02.011.
Endres M, Andreas K, Kalwitz G, Freymann U, Neumann K, Ringe J, et al.
Chemokine proﬁle of synovial ﬂuid from normal, osteoarthritis and rheumatoid
arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral
mesenchymal progenitor cells. Osteoarthritis Cartilage 2010;18(11):1458–66.
https://doi.org/10.1016/j.joca.2010.08.003.
Haringman JJ, Smeets TJM, Reinders-Blankert P, Tak PP. Chemokine and
chemokine receptor expression in paired peripheral blood mononuclear cells and
synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive
arthritis. Ann Rheum Dis 2006;65(3):294–300. https://doi.org/10.1136/
ard.2005.037176.
Ellman MB, Yan D, Ahmadinia K, Chen D, An HS, Im HJ. Fibroblast growth factor
control of cartilage homeostasis. J Cell Biochem 2013;114(4):735–42. https://
doi.org/10.1002/jcb.24418.
Chia S-L, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J, et al. Fibroblast
growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5
and delays cartilage degradation in murine osteoarthritis. Arthritis Rheum 2009;
60(7):2019–27. https://doi.org/10.1002/art.24654.
Wang M, Sampson ER, Jin H, Li J, Ke QH, Im H-J, et al. MMP13 is a critical target
gene during the progression of osteoarthritis. Arthritis Res Ther 2013;15(1):R5.
https://doi.org/10.1186/ar4133.
Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH. Regulation of
MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.
Osteoarthritis Cartilage 2004;12(12):963–73. https://doi.org/10.1016/
j.joca.2004.08.008.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted
disruption of Cbfa1 results in a complete lack of bone formation owing to
maturational arrest of osteoblasts. Cell 1997;89(5):755–64.
Shibata S, Suda N, Yoda S, Fukuoka H, Ohyama K, Yamashita Y, et al. Runx2deﬁcient mice lack mandibular condylar cartilage and have deformed Meckel’s
cartilage. Anat Embryol 2004;208(4):273–80. https://doi.org/10.1007/s00429004-0393-2.
Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, et al. Missense
mutations abolishing DNA binding of the osteoblast-speciﬁc transcription factor
OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997;16(3):307–10. https://
doi.org/10.1038/ng0797-307.
Liao L, Zhang S, Zhou G-Q, Ye L, Huang J, Zhao L, et al. Deletion of Runx2 in
condylar chondrocytes disrupts TMJ tissue homeostasis. J Cell Physiol 2019;
234(4):3436–44. https://doi.org/10.1002/jcp.26761.
Brophy RH, Rai MF, Zhang Z, Torgomyan A, Sandell LJ. Molecular analysis of age
and sex-related gene expression in meniscal tears with and without a concomitant
anterior cruciate ligament tear. J Bone Joint Surg Am 2012;94(5):385–93. https://
doi.org/10.2106/JBJS.K.00919.
Englund M, Roemer FW, Hayashi D, Crema MD, Guermazi A. Meniscus pathology,
osteoarthritis and the treatment controversy. Nat Rev Rheumatol 2012;8(7):
412–9. https://doi.org/10.1038/nrrheum.2012.69.
Muhammad H, Schminke B, Bode C, Roth M, Albert J, von der Heyde S, et al.
Human migratory meniscus progenitor cells are controlled via the TGF-β pathway.
Stem Cell Rep 2014;3(5):789–803. https://doi.org/10.1016/
j.stemcr.2014.08.010.
Hellio Le Graverand MP, Vignon E, Otterness IG, Hart DA. Early changes in lapine
menisci during osteoarthritis development: part I: cellular and matrix alterations.
Osteoarthritis Cartilage 2001;9(1):56–64. https://doi.org/10.1053/
joca.2000.0350.
Mauck RL, Martinez-Diaz GJ, Yuan X, Tuan RS. Regional multilineage
differentiation potential of meniscal ﬁbrochondrocytes: implications for meniscus
repair. Anat Rec 2007;290(1):48–58. https://doi.org/10.1002/ar.20419.
Fox AJS, Wanivenhaus F, Burge AJ, Warren RF, Rodeo SA. The human meniscus: a
review of anatomy, function, injury, and advances in treatment. Clin Anat 2015;
28(2):269–87. https://doi.org/10.1002/ca.22456.
Hunziker EB. Articular cartilage repair: basic science and clinical progress. a
review of the current status and prospects. Osteoarthritis Cartilage 2002;10(6):
432–63. https://doi.org/10.1053/joca.2002.0801.
Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM, et al. Inﬂammatory
cytokines associated with degenerative disc disease control aggrecanase-1
(ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB. Am J
Pathol 2013;182(6):2310–21. https://doi.org/10.1016/j.ajpath.2013.02.037.
Petersen W, Pufe T, St€arke C, Fuchs T, Kopf S, Raschke M, et al. Locally applied
angiogenic factors–a new therapeutic tool for meniscal repair. Ann Anat 2005;
187(5–6):509–19. https://doi.org/10.1016/j.aanat.2005.04.010.
Segawa Y, Muneta T, Makino H, Nimura A, Mochizuki T, Ju Y-J, et al.
Mesenchymal stem cells derived from synovium, meniscus, anterior cruciate

D. Chen et al.

[100]

[101]
[102]

[103]

[104]

[105]

[106]

[107]

[108]

[109]

[110]

[111]

[112]

[113]

[114]

[115]

[116]

[117]

[118]

Journal of Orthopaedic Translation 23 (2020) 132–139

ligament, and articular chondrocytes share similar gene expression proﬁles. J
Orthop Res 2009;27(4):435–41. https://doi.org/10.1002/jor.20786.
Liao L, Jiang H, Fan Y, Lu RS, Wei C, Takarada T, et al. Runx2 is required for
postnatal intervertebral disc tissue growth and development. J Cell Physiol 2019;
234(5):6679–87. https://doi.org/10.1002/jcp.27410.
Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell
Biol 2009;10(2):116–25. https://doi.org/10.1038/nrm2621.
Cao J, Han X, Qi X, Jin X, Li X. miR-204-5p inhibits the occurrence and
development of osteoarthritis by targeting Runx2. Int J Mol Med 2018;42(5):
2560–8. https://doi.org/10.3892/ijmm.2018.3811.
Zhao W, Zhang S, Wang B, Huang J, Lu WW, Chen D. Runx2 and microRNA
regulation in bone and cartilage diseases. Ann N Y Acad Sci 2016;1383(1):80–7.
https://doi.org/10.1111/nyas.13206.
Huang J, Zhao L, Xing L, Chen D. MicroRNA-204 regulates Runx2 protein
expression and mesenchymal progenitor cell differentiation. Stem Cell 2010;
28(2):357–64. https://doi.org/10.1002/stem.288.
Ji Q, Xu X, Xu Y, Fan Z, Kang L, Li L, et al. miR-105/Runx2 axis mediates FGF2induced ADAMTS expression in osteoarthritis cartilage. J Mol Med 2016;94(6):
681–94. https://doi.org/10.1007/s00109-016-1380-9.
Martinez-Sanchez A, Dudek KA, Murphy CL. Regulation of human chondrocyte
function through direct inhibition of cartilage master regulator SOX9 by
microRNA-145 (miRNA-145). J Biol Chem 2012;287(2):916–24. https://doi.org/
10.1074/jbc.M111.302430.
Tuddenham L, Wheeler G, Ntounia-Fousara S, Waters J, Hajihosseini MK, Clark I,
et al. The cartilage speciﬁc microRNA-140 targets histone deacetylase 4 in mouse
cells. FEBS Lett 2006;580(17):4214–7. https://doi.org/10.1016/
j.febslet.2006.06.080.
Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, et al. MicroRNA-140 plays
dual roles in both cartilage development and homeostasis. Genes Dev 2010;
24(11):1173–85. https://doi.org/10.1101/gad.1915510.
Tardif G, Hum D, Pelletier J-P, Duval N, Martel-Pelletier J. Regulation of the
IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human
osteoarthritic chondrocytes. BMC Muscoskel Disord 2009;10:148. https://doi.org/
10.1186/1471-2474-10-148.
Zhang D, Cao X, Li J, Zhao G. MiR-210 inhibits NF-κB signaling pathway by
targeting DR6 in osteoarthritis. Sci Rep 2015;5:12775. https://doi.org/10.1038/
srep12775.
Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and
prospects for epigenetic therapy. Nature 2004;429(6990):457–63. https://
doi.org/10.1038/nature02625.
Fern
andez-Tajes J, Soto-Hermida A, Vazquez-Mosquera ME, Cortes-Pereira E,
Mosquera A, Fernandez-Moreno M, et al. Genome-wide DNA methylation analysis
of articular chondrocytes reveals a cluster of osteoarthritic patients. Ann Rheum
Dis 2014;73(4):668–77. https://doi.org/10.1136/annrheumdis-2012-202783.
Ling M, Huang P, Islam S, Heruth DP, Li X, Zhang LQ, et al. Epigenetic regulation
of Runx2 transcription and osteoblast differentiation by nicotinamide
phosphoribosyltransferase. Cell Biosci 2017;7:27. https://doi.org/10.1186/
s13578-017-0154-6.
Li Y, Ge C, Franceschi RT. MAP kinase-dependent RUNX2 phosphorylation is
necessary for epigenetic modiﬁcation of chromatin during osteoblast
differentiation. J Cell Physiol 2017;232(9):2427–35. https://doi.org/10.1002/
jcp.25517.
Rushton MD, Reynard LN, Young DA, Shepherd C, Aubourg G, Gee F, et al.
Methylation quantitative trait locus analysis of osteoarthritis links epigenetics
with genetic risk. Hum Mol Genet 2015;24(25):7432–44. https://doi.org/
10.1093/hmg/ddv433.
arcOGEN Consortium, arcOGEN Collaborators, Zeggini E, Panoutsopoulou K,
Southam L, Rayner NW, et al. Identiﬁcation of new susceptibility loci for
osteoarthritis (arcOGEN): a genome-wide association study. Lancet 2012;
380(9844):815–23. https://doi.org/10.1016/S0140-6736(12)60681-3.
Rice SJ, Aubourg G, Sorial AK, Almarza D, Tselepi M, Deehan DJ, et al.
Identiﬁcation of a novel, methylation-dependent, RUNX2 regulatory region
associated with osteoarthritis risk. Hum Mol Genet 2018;27(19):3464–74. https://
doi.org/10.1093/hmg/ddy257.
Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating
expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms

[119]

[120]

[121]

[122]

[123]

[124]

[125]

[126]

[127]

[128]

[129]

[130]

[131]

[132]

[133]

[134]

[135]

[136]

139

that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot
Gene Expr 1996;6(4):391–411.
Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix
metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and
aggrecanase activities can be independent. J Clin Invest 1996;98(10):2292–9.
Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma H-L, et al. Deletion of
active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.
Nature 2005;434(7033):644–8. https://doi.org/10.1038/nature03369.
Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al.
ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature
2005;434(7033):648–52. https://doi.org/10.1038/nature03417.
Kashiwagi M, Enghild JJ, Gendron C, Hughes C, Caterson B, Itoh Y, et al. Altered
proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol
Chem 2004;279(11):10109–19. https://doi.org/10.1074/jbc.M312123200.
Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, et al.
Osteoarthritis development in novel experimental mouse models induced by knee
joint instability. Osteoarthritis Cartilage 2005;13(7):632–41. https://doi.org/
10.1016/j.joca.2005.03.004.
Selvamurugan N, Jefcoat SC, Kwok S, Kowalewski R, Tamasi JA, Partridge NC.
Overexpression of Runx2 directed by the matrix metalloproteinase-13 promoter
containing the AP-1 and Runx/RD/Cbfa sites alters bone remodeling in vivo. J Cell
Biochem 2006;99(2):545–57. https://doi.org/10.1002/jcb.20878.
Wong M, Siegrist M, Goodwin K. Cyclic tensile strain and cyclic hydrostatic
pressure differentially regulate expression of hypertrophic markers in primary
chondrocytes. Bone 2003;33(4):685–93.
Terauchi K, Kobayashi H, Yatabe K, Yui N, Fujiya H, Niki H, et al. The NADdependent deacetylase sirtuin-1 regulates the expression of osteogenic
transcriptional activator runt-related transcription factor 2 (Runx2) and
production of matrix metalloproteinase (MMP)-13 in chondrocytes in
osteoarthritis. Int J Mol Sci 2016;17(7). https://doi.org/10.3390/ijms17071019.
Tetsunaga T, Nishida K, Furumatsu T, Naruse K, Hirohata S, Yoshida A, et al.
Regulation of mechanical stress-induced MMP-13 and ADAMTS-5 expression by
RUNX-2 transcriptional factor in SW1353 chondrocyte-like cells. Osteoarthritis
Cartilage 2011;19(2):222–32. https://doi.org/10.1016/j.joca.2010.11.004.
Boumah CE, Lee M, Selvamurugan N, Shimizu E, Partridge NC. Runx2 recruits
p300 to mediate parathyroid hormone’s effects on histone acetylation and
transcriptional activation of the matrix metalloproteinase-13 gene. Mol Endocrinol
2009;23(8):1255–63. https://doi.org/10.1210/me.2008-0217.
Meyer MB, Benkusky NA, Pike JW. Selective distal enhancer control of the Mmp13
gene identiﬁed through clustered regularly interspaced short palindromic repeat
(CRISPR) genomic deletions. J Biol Chem 2015;290(17):11093–107. https://
doi.org/10.1074/jbc.M115.648394.
Takahashi A, de Andres MC, Hashimoto K, Itoi E, Otero M, Goldring MB, et al.
DNA methylation of the RUNX2 P1 promoter mediates MMP13 transcription in
chondrocytes. Sci Rep 2017;7(1):7771. https://doi.org/10.1038/s41598-01708418-8.
Mirando AJ, Liu Z, Moore T, Lang A, Kohn A, Osinski AM, et al. RBPjκ-dependent
Notch signaling is required for articular cartilage and joint maintenance. Arthritis
Rheum 2013;65(10):2623–33. https://doi.org/10.1002/art.38076.
Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health
dilemma. Nat Rev Rheumatol 2013;9(6):328–39. https://doi.org/10.1038/
nrrheum.2013.25.
Sassi N, Laadhar L, Allouche M, Achek A, Kallel-Sellami M, Makni S, et al. WNT
signaling and chondrocytes: from cell fate determination to osteoarthritis
physiopathology. J Recept Signal Transduct Res 2014;34(2):73–80. https://
doi.org/10.3109/10799893.2013.863919.
Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, et al. Matrix
metalloproteinase 13-deﬁcient mice are resistant to osteoarthritic cartilage erosion
but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum
2009;60(12):3723–33. https://doi.org/10.1002/art.25002.
Thirunavukkarasu K, Pei Y, Wei T. Characterization of the human ADAMTS-5
(aggrecanase-2) gene promoter. Mol Biol Rep 1AD;34(4). doi:10.1007/s11033006-9037-3
Yano F, Hojo H, Ohba S, Fukai A, Hosaka Y, Ikeda T, et al. A novel diseasemodifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis 2013;
72(5):748–53. https://doi.org/10.1136/annrheumdis-2012-201745.

